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The prognostic value of the Standardized Uptake Value (SUV) of 
FDG-PET in patients with stage I and II non-small cell lung cancer 
(NSCLC) treated by radical surgery
Rops, Maria J.; Maas, Klaartje W.; Schramel, Franz M.; Verzijlbergen, 
Fred J. 
St. Antonius Hospital, Nieuwegein, The Netherlands
Introduction: Patients with stage I or II NSCLC are candidates for 
surgery, resulting in 5-year survival ranging from 40 to 70%. How-
ever, even in resected stage I NSCLC, recurrence accounts for 57% 
of deaths! FDG-PET has become standard procedure in the diagnostic 
work-up of patients with (suspected) NSCLC. The aim of this study 
was to analyse the prognostic value of SUV of FDG-PET in patients 
with radical resected stage I and II NSCLC.
Methods: Primary endpoint of this retrospective study was time to 
recurrence after radical resection of stage I and II NSCLC in relation to 
the SUV on FDG-PET, pre-operatively used for staging purpose. Sec-
ondary endpoints were stage at presentation, histology, tumour size, oc-
currence of metastases during follow-up and overall survival in relation 
to the SUV. Statistics were performed by t-test and Kruskal-Wallis test.
Results: From the period of May 2003 until January 2005, 53 pa-
tients with radical resected stage I or II NSCLC were included. In 18 
patients who developed a recurrence, a strong inverse correlation was 
seen between SUV and time to recurrence (R=0.61; p<0.005), with a 
cut-off value of 7.0. There was no signiﬁcant relation between SUV 
with tumour size, histology, and the occurrence of metastases or overall 
survival. Patients with stage IIB NSCLC showed signiﬁcant higher 
SUV than patients with stage I NSCLC.
Conclusion: SUV of FDG-PET shows prognostic signiﬁcance in pre-
dicting the time to recurrence of radical resected stage I and II NSCLC. 
Prospective studies are needed to validate this predictive value. SUV 
could play an important role in the decision whether or not to treat 
patients after radical pulmonary resection for stage I or II NSCLC with 
adjuvant chemotherapy.
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Comparison of 5-year survival rate in surgically treated IB and IIA 
NSCLC patients
Rudzinski, Piotr M.; Kupis, Wlodzimierz R.; Orlowski, Tadeusz M. 
National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
Background: The group of patients operated on for N1 NSCLC is 
considered very heterogeneous in terms of 5-year survival rates.
Therefore we have decided to compare 5-year survival rates operated 
on at our institution for NSCLC in pathological stage of T2N0 and 
T1N1.
Methods: We reviewed retrospectively the data of 696 patients who 
underwent the lung resection for NSCLC in our institution between 
January 1998 and December 2000. In all of them the complete lymph-
adenectomy (hilar and mediastinal) was performed along with lung 
resection.
Results: The stage of the disease was estimated as IB in 181 pts 
(26,6%) and as IIA in 44 pts (6,3%). (N1 was conﬁrmed in 221pts out 
of 696 operated on). 5-year survival rate in IB and IIA groups was 61% 
and 54,5% respectively. We accepted the p value < 0,001 in log rank 
test as the statistically signiﬁcant.
We have found no statistically signiﬁcant inﬂuence of age (59,4% in 
<50 year old pts and 59,4% in >70y old pts, p<0.55), type of resection 
(63,8% in lobectomy, 56,3% in pneumonectomy, p<0.69), histology 
(59,7% in adenocarcinoma, 61,3% in squamous cell, p=0,93), T value 
(p=0.66), presence of neoplastic tromboli in lymphatic vessels (50% of 
positive, 61,1% if negative, p< 0,34) or inﬁltration of nerves (61% if 
negative, 47,1% if positive, p<0,28) on 5-year survival rate.
Among patient with N1 there was no statistically signiﬁcant differ-
ence between hilar and intrapulmonary lymphatic spread - the 5-year 
survival rate was 60,9% and 52,7% respectively (p<0,32). Each of 
these two groups of hilar lymphnodes were divided into two subgroups. 
There was also no statistically signiﬁcant difference within both of 
them. In hilar lymphnodes - groups 10 and 11 - the 5-year survival rate 
was 60.9% and 52.7% (p < 0.32) respectively and in intrapulmonary 
lymphnodes - groups 12 and 13 - 5-year survival rate was 51.5% and 
48.3% (p<0.56) respectively.
Marginal statistically signiﬁcant inﬂuence on 5-year survival rate we 
found comparing the sex of patients (M -55,1%, F - 61,1,%, p < 0,01) 
and presence of neoplastic emboli in blood vessels (52,6% if positive 
and 64,4% if negative, p < 0.08).
Conclusions: The lack of statistically signiﬁcant differences between 
these two groups of patients let us suggest combining them into one 
group.
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What are the factors that determine prognosis of recurrent non-
small cell lung cancer after curative surgery?
Sakuragi, Tohru; Furutachi, Akira; Mitsuoka, Masahiro; Itoh, Tsuyoshi 
Thoracic and Cardivascular Surgery, Saga University, Saga, Japan
Objective: Recurrence of non-small cell lung cancer (NSCLC) after 
surgery is difﬁcult to prevent. Although many cases are fatal within a 
short time period, other individuals survive for long periods after the 
recurrence. The aim of this study was to investigate the factors that 
inﬂuence prognosis of recurrent NSCLC.
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Methods: The medical records of 443 patients who underwent curative 
resection for NSCLC at our institution between 1994 and 2004 were re-
viewed retrospectively. The tumor recurrence and 12 clinicopathologi-
cal factors, which may affect prognosis after recurrence, were analyzed 
using univariate and multivariate analyses. The factors assessed were: 
age, sex, tumor histology, neoadjuvant therapy, adjuvant therapy, patho-
logical stage of the initial curative resection, the patient’s acceptance of 
the treatment for the recurrent tumor, surgical method, time from initial 
surgery to recurrence, locoregional vs. distant recurrence, recurrence in 
a single organ vs. multiple, recurrence only in the lung vs. in the lung 
and/or other organ(s). 
Results: Recurrence occurred in 176 patients (39.7 %) during the 
mean follow-up period of 1.54 years. There were 129 males and 47 
females (mean age 66 yrs). The histological types were adenocarci-
noma (n=100), squamous cell carcinoma (n=60), large cell carcinoma 
(n=8), and other histological types (n=8). Ninety-four patients (53.4 %) 
had recurrence in a single organ when the recurrence was ﬁrst identi-
ﬁed; lung in 30 patients, bone in 14, brain in 11 and other organs in 39 
patients. Recurrence occurred at 1.44 years (median, range 0.1-10.0) 
after the curative operation. Median survival time was 8.4 months and 
overall 2-yr survival rate after recurrence was 34.8 %. Multivariate 
analysis showed that adenocarcinoma (p<0.0001), recurrence only in 
the lung (p=0.001), a longer time from initial surgery to recurrence 
(p=0.042) and the patient’s acceptance of the treatment for the recurrent 
tumor (p<0.0001), were signiﬁcant independent factors for improved 
prognosis. Patients with more than one of the four factors had a sig-
niﬁcantly better prognosis after recurrence. (Graph; the difference in 
survival between subgroups was statistically signiﬁcant. p= .012 for 
all factors vs. 2 or 3 factors, p< .0001 for 2 or 3 factors vs. 1 factor, p= 
.0026 for 1 factor vs. no factors).
Conclusion: Some factors for positive prognosis after NSCLC recur-
rence have been identiﬁed. Establishment of more effective treatment 
for patients with non-adenocarcinoma or extrapulmonary recurrence 
may improve prognosis of patients with recurrent NSCLC after cura-
tive resection.
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Intentional segmentectomy for NSCLC accompanied by surgical 
margin cytological examination
Sawabata, Noriyoshi1 Maeda, Hajime2 Kobayashi, Satoru1 Ishihama, 
Yoshimi1 Okumura, Meinoshin3 Miyoshi, Shinichiro1 
1 Department of Cardio-Thoracic Surgery, Dokkyo Med. University 
School of Medicine, Mibu, Japan 2 Department of Surgery for Chest 
Diseases, National Toneyama Hospital, Toyonaka, Japan 3 Department 
of Surgery, Osaka University Graduate School of Medicine, Suita, Japan 
Background: A segmentectomy is a less invasive option to treat non-
small cell lung cancer (NSCLC), as is a wedge resection, in which 
local/regional relapse should be avoided. A malignant margin is an 
indicator of surgical margin relapse, even when histological ﬁndings 
are negative for a malignant margin. Thus, a cytological examination 
is considered mandatory in cases of intentional segmentectomy for 
NSCLC. We performed intentional segmentectomies for clinical stage 
IA NSCLC and conﬁrmed complete resection at the surgical margin 
using a cytological method.
Methods: Intentional segmentectomies were performed in patients 
with clinical stage IA NSCLC and we analyzed the results of those who 
met the following criteria: 1) tumor size less than 2 cm, 2) no signs of 
visceral pleura invasion, 3) no evidence of metastases in dissected hilar 
and/or mediastinal lymph nodes shown by a frozen section histological 
examination, 4) negative results in a surgical margin cytology exami-
nation using the run-across method (Figure 1) during surgery, and 5) 
completion lobectomy performed in cases with a malignant positive 
margin and/or lymph node metastasis.
Results: From 2001 to 2007, we carried out 22 intentional segmentec-
tomies in patients that met the study criteria. The median tumor size 
was 1.7 cm (range, 1.2-2.0 cm), and the tumor histology was adeno-
carcinoma in 17 cases and squamous cell carcinoma in 5. The tumor 
location was right S1 in 2, right S6 in 5, right S8 in 1, left S1+2 in 3, 
left S4 in 2, left S5 in 2, and left S6 in 7 cases. All operations were 
performed using an axillar thoracotomy, and the method of parenchyma 
division was a stapler in 17 cases and electronic knife in 5. Two cases 
had malignant positive margin cytology ﬁndings, both of which had 
a tumor location in right S6 (stapler 1, electronic knife 1), though no 
metastasized lymph nodes were found. There was a median follow-up 
period of 36 months, during which there was 1 death, due to a thoracic 
aortic aneurysm rupture. Thus, the 3-year disease speciﬁc survival rate 
was 100% and the overall 3-year survival rate was 90%, while there 
were no instances of local/regional relapse.
